1399-3038/asset/olbannerleft.gif?v=1&s=89feb8fdf43522e65684dcd181d346e1b33b8efe)
1399-3038/asset/olbannerright.gif?v=1&s=ca4a551e650c8254026acfe589ae42d017ea70b4)
Original Article
You have free access to this content
Subcutaneous immunoglobulin: rapid push vs. infusion pump in pediatrics
Article first published online: 20 JAN 2013
DOI: 10.1111/pai.12026
© 2013 John Wiley & Sons A/S. Published by Blackwell Publishing Ltd
Additional Information
How to Cite
. Subcutaneous immunoglobulin: rapid push vs. infusion pump in pediatrics. Pediatr Allergy Immunol 2013: 24: 49–53.
Publication History
- Issue published online: 20 JAN 2013
- Article first published online: 20 JAN 2013
- Manuscript Accepted: 22 OCT 2012
References
- 1. Subcutaneous administration of IgG. Immunol Allergy Clin North Am 2008: 28: 779–802.
- 2, , , et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol 2004: 114: 936–42.
- 3, , , et al. Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol 2006: 26: 65–72.
- 4, , , et al. Improved quality of life, immunoglobulin G levels, and infection rate in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G. South Med J 2010: 103: 856–63.
- 5, , , et al. Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency. Eur J Med Res 2010: 15: 238–45.
- 6
- 7. Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes. Immunol Allergy Clin North Am 2008: 28: 803–19.
- 8. Subcutaneous immunoglobulin therapy by rapid push is preferred to infusion by pump: a retrospective analysis. J Clin Immunol 2010: 30: 301–7.
- 9American Academy of Allergy, Asthma and Immunology. Position statement on the appropriate use of intravenously administered immunoglobulin (IGIV). January 2005. Available at: http://www.aaaai.org/Aaaai/media/MediaLibrary/PDF%20Documents/Practice%20and%20Parameters/IGIV-2005.pdf. Accessed September 25, 2012.
- 10Vivaglobin Prescribing Information. Marburg, Germany: CSL Behring GmbH, 2010.
- 11Hizentra [package insert]. Bern, Switzerland: CSL Behring AG, 2011.
- 12European Agency for the Evaluation of Medicinal Products (EMEA), Committee for Proprietary Medicinal Products (CPMP). Note for guidance on the clinical investigation of human normal immunoglobulin for subcutaneous and intramuscular use, 2002. EMEA/CPMP/BPWG/282/00. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/10/WC500004255.pdf. Accessed May 14, 2012.
- 13. IgG replacement therapy, no size fits all. Clin Immunol 2011: 139: 107–9.
- 14, , , et al. Efficacy and safety of 20% SCIG, a New 20% Immunoglobulin preparation for subcutaneous administration, in pediatric patients with primary immunodeficiency. J Clin Immunol 2011b: 31: 752–61.
- 15, , , et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies—a prospective, multi-national study. J Clin Immunol 2006: 26: 177–85.
- 16, , , et al. Efficacy and safety of Hizentra® in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy. Clin Immunol 2011b: 141: 102.
- 17, , , . A pilot study of equal doses of 10% IGIV given intravenously or subcutaneously. J Allergy Clin Immunol 2009: 124: 854–6.
- 18, . Factors affecting infusion of high (20%) vs. lower concentration (16%) SCIg in primary immunodeficiency disorders [abstract]. Annual Meeting of the American Academy of Allergy Asthma & Immunology; Orlando, FL, March 2-6, 2012.